Goa K L, Balfour J A
Adis International Limited, Auckland, New Zealand.
Drugs Aging. 1998 Jul;13(1):83-91; discussion 92. doi: 10.2165/00002512-199813010-00008.
Risedronate is a pyridinyl bisphosphonate that can be administered orally in lower dosages than other antiresorptive bisphosphonates. Like others of its class risedronate inhibits osteoclast-mediated bone resorption. In experimental models of osteoporosis, risedronate inhibited bone loss and improved trabecular architecture. In patients with Paget's disease, pain diminished or disappeared and serum alkaline phosphatase levels decreased after treatment with oral risedronate 30 mg/day for < or = 3 months. Risedronate 30 mg/day orally for 2 months significantly reduced pain, whereas etidronate 400 mg/day orally for 6 months tended to reduce pain, in a randomised double-blind trial of patients with Paget's disease. Oral risedronate 5 mg/day for < or = 2 years increased bone mass in postmenopausal women with low or normal bone mass. Risedronate 2.5 mg/day prevented bone loss in postmenopausal women treated with glucocorticoids for rheumatoid arthritis. The incidence of gastrointestinal or other adverse events was similar in patients treated with risedronate or placebo in clinical trials.
利塞膦酸盐是一种吡啶基双膦酸盐，其口服剂量低于其他抗吸收性双膦酸盐。与同类其他药物一样，利塞膦酸盐可抑制破骨细胞介导的骨吸收。在骨质疏松症实验模型中，利塞膦酸盐可抑制骨质流失并改善小梁结构。在佩吉特病患者中，每日口服30mg利塞膦酸盐治疗≤3个月后，疼痛减轻或消失，血清碱性磷酸酶水平下降。在一项针对佩吉特病患者的随机双盲试验中，每日口服30mg利塞膦酸盐2个月可显著减轻疼痛，而每日口服400mg依替膦酸盐6个月则倾向于减轻疼痛。对于骨量低或正常的绝经后女性，每日口服5mg利塞膦酸盐≤2年可增加骨量。每日2.5mg利塞膦酸盐可预防因类风湿关节炎接受糖皮质激素治疗的绝经后女性骨质流失。在临床试验中，接受利塞膦酸盐或安慰剂治疗的患者发生胃肠道或其他不良事件的发生率相似。
